Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: .FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the "Inducement Plan"). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.
加利福尼亞州福斯特市，2025年1月2日（環球新聞通訊社）—— Terns製藥公司（「Terns」或「公司」）（納斯達克：TERN）是一家臨牀階段的生物製藥公司，致力於開發一系列小分子藥物候選品，旨在應對包括腫瘤學和肥胖症在內的嚴重疾病。今天，公司宣佈自2025年1月1日起，根據修訂後的2022年就業誘導獎計劃（「誘導計劃」），向一名新員工授予了一項股權誘導獎勵。該股權獎勵已獲得公司董事會薪酬委員會的批准，符合納斯達克上市規則5635(c)(4)，並作爲該員工接受公司工作的重大誘因。
The Company granted options to purchase 9,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $5.54, which was the closing price of Terns' common stock on December 31, 2024, which was the last trading day prior to the date of grant. The options vest over four years, subject to the employee's continued service through the applicable vesting dates.
公司向新員工授予了購買9,000股Terns普通股票的期權。這些期權的有效期爲10年，行使價格爲每股5.54美元，這是2024年12月31日Terns普通股票的收盤價，該日爲授予日期之前的最後一個交易日。這些期權將在四年內歸屬，前提是員工在適用的歸屬日期內繼續服務。
About Terns Pharmaceuticals
關於Terns製藥公司
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: .
Terns製藥公司是一家臨牀階段的生物製藥公司，致力於開發一系列小分子藥物候選品，針對包括腫瘤學和肥胖症在內的嚴重疾病。Terns的管線包含三個臨牀階段的開發項目，包括一種變構BCR-ABL抑制劑、一種小分子GLP-1受體激動劑、一種THR-β激動劑，以及一項針對GIPR調節劑的前臨牀發現工作，優先提名GIPR拮抗劑候選物。有關更多信息，請訪問：。
Contacts for Terns
Terns的聯繫人
Investors
Justin Ng
investors@ternspharma.com
投資者
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
媒體
珍娜·厄本
貝瑞與公司公共關係
media@ternspharma.com
譯文內容由第三人軟體翻譯。
